365565-88-4Relevant academic research and scientific papers
Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N′-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo
Xu, Ying,Wang, Ning-Yu,Song, Xue-Jiao,Lei, Qian,Ye, Ting-Hong,You, Xin-Yu,Zuo, Wei-Qiong,Xia, Yong,Zhang, Li-Dan,Yu, Luo-Ting
, p. 4333 - 4343 (2015/08/03)
FLT3 inhibitors have been explored as a viable therapy for acute myeloid leukemia (AML). However, the clinical outcomes of these FLT3 inhibitors were underwhelming except AC220. Therefore, the development of novel FLT3 inhibitors with high potency against
Novel human histamine H(3) receptor antagonists.
Shah, Chandra,McAtee, Laura,Breitenbucher, J Guy,Rudolph, Dale,Li, Xiaobing,Lovenberg, Timothy W,Mazur, Curt,Wilson, Sandy J,Carruthers, Nicholas I
, p. 3309 - 3312 (2007/10/03)
High throughput screening, using the recombinant human H(3) receptor, was used to identify novel histamine H(3) receptor antagonists. Evaluation of the lead compounds ultimately afforded potent, selective, orally bioavailable compounds (e.g., 38) with fav
